A detailed history of Consolidated Portfolio Review Corp transactions in Abb Vie Inc. stock. As of the latest transaction made, Consolidated Portfolio Review Corp holds 1,855 shares of ABBV stock, worth $308,894. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,855
Previous 3,053 39.24%
Holding current value
$308,894
Previous $473 Million 28.6%
% of portfolio
0.09%
Previous 0.11%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 30, 2024

SELL
$159.82 - $182.1 $191,464 - $218,155
-1,198 Reduced 39.24%
1,855 $338 Million
Q4 2023

Jan 29, 2024

SELL
$137.6 - $154.97 $26,694 - $30,064
-194 Reduced 5.97%
3,053 $473 Million
Q3 2023

Nov 13, 2023

BUY
$133.59 - $154.65 $14,160 - $16,392
106 Added 3.37%
3,247 $484 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $132 - $164
-1 Reduced 0.03%
3,141 $423 Million
Q1 2023

May 11, 2023

BUY
$144.61 - $166.54 $454,364 - $523,268
3,142 New
3,142 $501 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $294B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Consolidated Portfolio Review Corp Portfolio

Follow Consolidated Portfolio Review Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Consolidated Portfolio Review Corp, based on Form 13F filings with the SEC.

News

Stay updated on Consolidated Portfolio Review Corp with notifications on news.